Lineage Cell Therapeutics’ (LCTX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research note issued to investors on Tuesday,Benzinga reports. D. Boral Capital currently has a $2.00 price objective on the stock.

LCTX has been the topic of several other reports. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, February 11th. Maxim Group decreased their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th.

Lineage Cell Therapeutics Stock Down 0.0 %

NYSEAMERICAN LCTX opened at $0.52 on Tuesday. The firm has a market cap of $114.62 million, a price-to-earnings ratio of -4.33 and a beta of 1.21. The stock has a fifty day moving average of $0.60. Lineage Cell Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Defender Capital LLC. lifted its holdings in shares of Lineage Cell Therapeutics by 19.2% during the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock worth $2,997,000 after acquiring an additional 961,150 shares during the period. Geode Capital Management LLC lifted its holdings in Lineage Cell Therapeutics by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after purchasing an additional 83,274 shares during the last quarter. Barclays PLC lifted its holdings in Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after purchasing an additional 159,924 shares during the last quarter. State Street Corp lifted its holdings in Lineage Cell Therapeutics by 1.8% during the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after purchasing an additional 45,483 shares during the last quarter. Finally, Atria Wealth Solutions Inc. bought a new position in Lineage Cell Therapeutics during the 4th quarter valued at about $29,000. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.